Roberts MS, Anstine LJ, Finke VS, Bryson BL, et al. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene. Breast Cancer Res 2020;22:66.
PMID: 32552913